Do analysts rate PLUR or AADI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PLUR or AADI more profitable?

Aadi Bioscience has a net margin of -246.06% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Aadi Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Aadi Bioscience -246.06% -71.87% -57.28%

Do analysts prefer PLUR or RANI?

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 1,011.82%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is PLUR or RANI more profitable?

Rani Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Rani Therapeutics N/A -206.46% -83.95%

Do analysts prefer KLRS or PLUR?

Kalaris Therapeutics presently has a consensus price target of $15.60, suggesting a potential upside of 242.11%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PLUR or FTLF?

FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 92.03%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation and earnings, PLUR or FTLF?

FitLife Brands has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.08M 23.70 -$22.58M -$4.53 N/A FitLife Brands $81.46M 1.29 $6.33M $0.60 18.66

Is PLUR or FTLF more profitable?

FitLife Brands has a net margin of 6.64% compared to Pluri's net margin of -2,162.08%. FitLife Brands' return on equity of 18.31% beat Pluri's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% FitLife Brands 6.64% 18.31% 8.21%

Do analysts rate PEPG or PLUR?

PepGen currently has a consensus price target of $11.60, suggesting a potential upside of 670.25%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, PEPG or PLUR?

Pluri has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Pluri $1.08M 23.70 -$22.58M -$4.53 N/A

Is PEPG or PLUR more profitable?

PepGen has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Pluri -2,162.08% N/A -106.59%

Pluri (PLUR) Competitors

$2.37 +0.10 (+4.41%)

As of 12:12 PM Eastern

Compare

PLUR vs. AADI, RANI, KLRS, FTLF, and PEPG

Should you buy Pluri stock or one of its competitors? MarketBeat compares Pluri with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pluri include Aadi Bioscience (AADI), Rani Therapeutics (RANI), Kalaris Therapeutics (KLRS), FitLife Brands (FTLF), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry.

How does Pluri compare to Aadi Bioscience?

Pluri (NASDAQ:PLUR) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

16.6% of Pluri shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aadi Bioscience has a net margin of -246.06% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

In the previous week, Pluri had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Aadi Bioscience. Pluri's average media sentiment score of 1.87 beat Aadi Bioscience's score of 0.00 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
Aadi Bioscience	Neutral

Pluri has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.08M	23.70	-$22.58M	-$4.53	N/A
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A

Summary

Pluri beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.

How does Pluri compare to Rani Therapeutics?

Pluri (NASDAQ:PLUR) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 1,011.82%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Pluri has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Rani Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Rani Therapeutics	N/A	-206.46%	-83.95%

In the previous week, Rani Therapeutics had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Rani Therapeutics and 1 mentions for Pluri. Rani Therapeutics' average media sentiment score of 1.89 beat Pluri's score of 1.87 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pluri	Very Positive
Rani Therapeutics	Very Positive

Pluri has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.08M	23.70	-$22.58M	-$4.53	N/A
Rani Therapeutics	$3.17M	30.77	-$29.67M	-$0.41	N/A

16.6% of Pluri shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Rani Therapeutics beats Pluri on 12 of the 16 factors compared between the two stocks.

How does Pluri compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Pluri has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Kalaris Therapeutics presently has a consensus price target of $15.60, suggesting a potential upside of 242.11%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 1 mentions for Pluri. Pluri's average media sentiment score of 1.87 beat Kalaris Therapeutics' score of 0.42 indicating that Pluri is being referred to more favorably in the news media.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Pluri	Very Positive

Kalaris Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Pluri	-2,162.08%	N/A	-106.59%

Pluri has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Pluri	$1.08M	23.70	-$22.58M	-$4.53	N/A

Summary

Kalaris Therapeutics beats Pluri on 10 of the 16 factors compared between the two stocks.

How does Pluri compare to FitLife Brands?

Pluri (NASDAQ:PLUR) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 92.03%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

16.6% of Pluri shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 61.4% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

FitLife Brands has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.08M	23.70	-$22.58M	-$4.53	N/A
FitLife Brands	$81.46M	1.29	$6.33M	$0.60	18.66

In the previous week, FitLife Brands had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for FitLife Brands and 1 mentions for Pluri. Pluri's average media sentiment score of 1.87 beat FitLife Brands' score of 0.93 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
FitLife Brands	Positive

FitLife Brands has a net margin of 6.64% compared to Pluri's net margin of -2,162.08%. FitLife Brands' return on equity of 18.31% beat Pluri's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
FitLife Brands	6.64%	18.31%	8.21%

Summary

FitLife Brands beats Pluri on 12 of the 16 factors compared between the two stocks.

How does Pluri compare to PepGen?

PepGen (NASDAQ:PEPG) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

58.0% of PepGen shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 1.3% of PepGen shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PepGen has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Pluri has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

In the previous week, PepGen and PepGen both had 1 articles in the media. Pluri's average media sentiment score of 1.87 beat PepGen's score of 0.94 indicating that Pluri is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Positive
Pluri	Very Positive

PepGen has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Pluri	-2,162.08%	N/A	-106.59%

PepGen currently has a consensus price target of $11.60, suggesting a potential upside of 670.25%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pluri has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Pluri	$1.08M	23.70	-$22.58M	-$4.53	N/A

Summary

PepGen beats Pluri on 8 of the 14 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.57M	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.52	20.08	24.01	24.71
Price / Sales	23.70	326.19	540.55	165.59
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-21.55	8.11	10.55	6.85
Net Income	-$22.58M	$23.89M	$3.56B	$337.45M
7 Day Performance	2.60%	3.36%	1.54%	2.70%
1 Month Performance	-29.67%	1.34%	2.48%	4.60%
1 Year Performance	-46.01%	46.46%	26.49%	32.81%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	0.6207 of 5 stars	$2.37 +4.4%	N/A	-48.3%	$25.57M	$1.08M	N/A	150	Positive News
AADI Aadi Bioscience	N/A	$4.02 -3.1%	N/A	+112.2%	$99.28M	$25.07M	N/A	40
RANI Rani Therapeutics	3.1325 of 5 stars	$0.80 -1.4%	$8.75 +993.8%	+44.7%	$99.23M	$1.63M	N/A	110	News Coverage Positive News Gap Up
KLRS Kalaris Therapeutics	4.111 of 5 stars	$4.12 +0.7%	$15.60 +278.7%	+64.0%	$97.80M	N/A	N/A	110	News Coverage Analyst Downgrade
FTLF FitLife Brands	4.5247 of 5 stars	$10.31 +0.9%	$21.50 +108.6%	-21.4%	$97.71M	$81.46M	17.23	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors

PLUR vs. AADI, RANI, KLRS, FTLF, and PEPG

How does Pluri compare to Aadi Bioscience?

Summary

How does Pluri compare to Rani Therapeutics?

Summary

How does Pluri compare to Kalaris Therapeutics?

Summary

How does Pluri compare to FitLife Brands?

Summary

How does Pluri compare to PepGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pluri (PLUR) Competitors

PLUR vs. AADI, RANI, KLRS, FTLF, and PEPG

How does Pluri compare to Aadi Bioscience?

Do institutionals & insiders hold more shares of PLUR or AADI?

Do analysts rate PLUR or AADI?

Is PLUR or AADI more profitable?

Which has more risk & volatility, PLUR or AADI?

Does the media refer more to PLUR or AADI?

Which has better valuation & earnings, PLUR or AADI?

Summary

How does Pluri compare to Rani Therapeutics?

Do analysts prefer PLUR or RANI?

Which has more risk & volatility, PLUR or RANI?

Is PLUR or RANI more profitable?

Does the media refer more to PLUR or RANI?

Which has better earnings and valuation, PLUR or RANI?

Do insiders and institutionals believe in PLUR or RANI?

Summary

How does Pluri compare to Kalaris Therapeutics?

Do institutionals and insiders have more ownership in KLRS or PLUR?

Which has more volatility and risk, KLRS or PLUR?

Do analysts prefer KLRS or PLUR?

Does the media favor KLRS or PLUR?

Is KLRS or PLUR more profitable?

Which has better valuation & earnings, KLRS or PLUR?

Summary

How does Pluri compare to FitLife Brands?

Do analysts recommend PLUR or FTLF?

Do institutionals & insiders believe in PLUR or FTLF?

Which has more volatility and risk, PLUR or FTLF?

Which has preferable valuation and earnings, PLUR or FTLF?

Does the media refer more to PLUR or FTLF?

Is PLUR or FTLF more profitable?

Summary

How does Pluri compare to PepGen?

Do insiders and institutionals hold more shares of PEPG or PLUR?

Which has more risk & volatility, PEPG or PLUR?

Does the media prefer PEPG or PLUR?

Is PEPG or PLUR more profitable?

Do analysts rate PEPG or PLUR?

Which has preferable valuation and earnings, PEPG or PLUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools